An update from StemRIM Inc. ( (JP:4599)) is now available. StemRIM Inc. announced that partner Shionogi & Co. has completed patient enrollment in a global Phase 2b clinical trial of Redasemtide ...

StemRIM Inc. has secured a substance patent in Australia for peptides linked to its Redasemtide product, enhancing its market position by preventing the creation of generic and counterfeit drugs. This ...

SHIONOGI/StemRIM's Redasemtide is a regenerative therapy in development that promotes tissue repair without relying on living cells. It has received Orphan Drug Designation for DEB from the MHLW.